BIOGEN INC. Servicing Asset at Fair Value, Changes in Fair Value Resulting from Changes in Valuation Inputs or Changes in Assumptions
BIOGEN INC. (BIIB) reported Servicing Asset at Fair Value, Changes in Fair Value Resulting from Changes in Valuation Inputs or Changes in Assumptions of $0 for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-04-23.
Discontinued › Notes
us-gaap:ServicingAssetAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions · last filed 2020-04-23
- BIOGEN INC. servicing asset at fair value, changes in fair value resulting from changes in valuation inputs or changes in assumptions for the quarter ending 2020-03-31 was $0.00.
- BIOGEN INC. servicing asset at fair value, changes in fair value resulting from changes in valuation inputs or changes in assumptions for the quarter ending 2019-09-30 was $0.00.
| Period end | Servicing Asset at Fair Value, Changes in Fair Value Resulting from Changes in Valuation Inputs or Changes in Assumptions 3 month | Servicing Asset at Fair Value, Changes in Fair Value Resulting from Changes in Valuation Inputs or Changes in Assumptions 6 month | Servicing Asset at Fair Value, Changes in Fair Value Resulting from Changes in Valuation Inputs or Changes in Assumptions 9 month |
|---|---|---|---|
| 2020-03-31 | $0.00 10-Q · filed 2020-04-23 | ||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-22 | $0.00 10-Q · filed 2019-10-22 | |
| 2019-06-30 | $0.00 10-Q · filed 2019-07-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |